תוצאות חיפוש - S.R. Schwid

  • Showing 1 - 5 results of 5
Refine Results
  1. 1
    Cost-effectiveness of disease-modifying therapy for multiple sclerosis

    Cost-effectiveness of disease-modifying therapy for multiple sclerosis מאת Katia Noyes, Alina Bajorska, A T Chappel, S. R. Schwid, Lahar Mehta, Bianca Weinstock‐Guttman, Robert G. Holloway, Andrew W. Dick

    יצא לאור 2011
    קבל טקסט מלא
    Artigo
    הוספה למועדפים
    שמור ב:
  2. 2
    Enhanced Benefit of Increasing Interferon Beta-1a Dose and Frequency in Relapsing Multiple Sclerosis

    Enhanced Benefit of Increasing Interferon Beta-1a Dose and Frequency in Relapsing Multiple Sclerosis מאת Steven R. Schwid, John Thorpe, Mohammad K. Sharief, Magnhild Sandberg‐Wollheim, Kottil Rammohan, Jeanette Wendt, Hillel S. Panitch, Douglas S. Goodin, David Li, Peter Chang, Gordon Francis

    יצא לאור 2005
    קבל טקסט מלא קבל טקסט מלא
    Artigo
    הוספה למועדפים
    שמור ב:
  3. 3
    Multicenter randomized clinical trial of donepezil for memory impairment in multiple sclerosis

    Multicenter randomized clinical trial of donepezil for memory impairment in multiple sclerosis מאת Lauren Krupp, Christopher Christodoulou, Patricia Melville, W. F. Scherl, L.-Y. Pai, L.R. Muenz, Dian He, R.H.B. Benedict, Andrew Goodman, Syed Rizvi, S.R. Schwid, Bianca Weinstock‐Guttman, Holly James Westervelt, H. Wishart

    יצא לאור 2011
    קבל טקסט מלא
    Artigo
    הוספה למועדפים
    שמור ב:
  4. 4
    Serum Urate as a Predictor of Clinical and Radiographic Progression in Parkinson Disease

    Serum Urate as a Predictor of Clinical and Radiographic Progression in Parkinson Disease מאת Michael A. Schwarzschild, Steven R. Schwid, Kenneth Marek, Arthur Watts, Anthony E. Lang, David Oakes, Ira Shoulson, Alberto Ascherio, Christopher Hyson, Emily Gorbold, Alice Rudolph, Karl Kieburtz, Stanley Fahn, Lisa Gauger, Christopher G. Goetz, John Seibyl, M. Forrest, John Ondrasik

    יצא לאור 2008
    קבל טקסט מלא
    Artigo
    הוספה למועדפים
    שמור ב:
  5. 5
    Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trials

    Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trials מאת Andrew Goodman, François Béthoux, Theodore R. Brown, Randall T. Schapiro, Ron Cohen, Lawrence N. Marinucci, Herbert R. Henney, Andrew R. Blight, Mark Agius, B. G. W. Arnason, F. Béthoux, C. T. Bever, JD Bowen, TR Brown, D. Dietrich, Kelly Edwards, MS Freedman, Mark S. Freedman, NJ Kachuck, MD Kaufman, Marshall J. Keilson, Omar Khan, Lauren Krupp, TP Leist, John Lindsey, F.D. Lublin, MK Mass, D. E. Mattson, Denise McGowan, Robert T. Naismith, Colleen O’Connell, JJ Oger, Hillel S. Panitch, MA Picone, K Rammohan, RT Schapiro, S.R. Schwid, Thomas F. Scott, C Short, BW Thrower, TL Vollmer, Ann Camac, JA Cooper, WF Chumley, Anne H. Cross, RT Dunnigan, JS Gitt, Marij A. Hillen, DR Jeffrey, B. Khatri, Kiren Kresa-Reahl, Seok Whan Moon, Jana Lízrová Preiningerová, Mark Tullman, Bianca Weinstock‐Guttman, DR Wynn

    יצא לאור 2015
    קבל טקסט מלא
    Artigo
    הוספה למועדפים
    שמור ב:

כלי חיפוש: